National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Ketoconazole (Ketoconazole HRA®). HTA ID: 21046

Ketoconazole (Ketoconazole HRA®) is indicated for the treatment of endogenous Cushing’s syndrome in adults and adolescents above the age of 12 years.



NCPE Assessment Process Complete
Rapid review commissioned 26/10/2021
Rapid review completed 13/12/2021
Rapid Review outcome A full HTA is not recommended. The NCPE recommends that ketoconazole not be considered for reimbursement at the submitted price*.


*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.